TERAZOL 3
LOE ApproachingNDAVAGINALCREAM
Approved
Feb 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TERAZOL 3 is a vaginal antifungal cream approved in 1991 for treatment of vulvovaginal candidiasis (yeast infections). The product is a small-molecule antifungal administered topically as a 3-day cream regimen. It represents a mature, well-established treatment option in the vaginal antifungal category.
LOE Approaching
Mature product approaching loss of exclusivity with moderate competitive pressure (30/100), likely smaller, maintenance-focused commercial team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TERAZOL 3 offers stability in a mature product but limited growth trajectory, with focus on market defense and cost optimization rather than expansion. Positions are likely focused on maintaining market share against generics and OTC alternatives in a declining revenue environment.
Brand ManagerField Sales Representative
Worked on TERAZOL 3 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.